We speculate in this paper thatCXCL5 could also mediate other obesity, and diabetes-derived pathologies,such as cardiovascular disease, retinopathy, or inflammatory bowel disease.In this scenario CXCL5 targeted therapy would prevent not only thedevelopment of type II diabetes in obese subjects, but also several otherobesity-related co morbidities. Here, CXCL5 is linked to inflammatory bowel disease.